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Reactive oxygen speciesReactive oxygen species (ROS) contain one or more unpaired electrons and are formed as intermediates in a
variety of normal biochemical reactions. However, when generated in excess amounts or not appropriately
controlled, ROS initiate extensive cellular damage and tissue injury. ROS have been implicated in the
progression of cancer, cardiovascular disease and neurodegenerative and neuroinﬂammatory disorders, such
as multiple sclerosis (MS). In the last decade there has been a major interest in the involvement of ROS in MS
pathogenesis and evidence is emerging that free radicals play a key role in various processes underlying MS
pathology. To counteract ROS-mediated damage, the central nervous system is equipped with an intrinsic
defense mechanism consisting of endogenous antioxidant enzymes. Here, we provide a comprehensive
overview on the (sub)cellular origin of ROS during neuroinﬂammation as well as the detrimental effects of
ROS in processing underlying MS lesion development and persistence. In addition, we will discuss clinical
and experimental studies highlighting the therapeutic potential of antioxidant protection in the
pathogenesis of MS.l Biology and Immunology, VU
7, 1007 MB Amsterdam, The
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Reactive oxygen species (ROS) are small molecules which are
highly reactive due to presence of unpaired electrons or their ability to
give rise to new free radicals. Many different forms of ROS exist, with
superoxide (O2−) and its derivatives hydroxyl radical (OH∙) and
hydrogen peroxide (H2O2) being most abundant in eukaryotic cells.
Superoxide can be formed both enzymatically by for instance NAD(P)
H oxidase, and non-enzymatically as a by-product of oxidative
phosphorylation [1]. Superoxide has a short life span and is either
rapidly converted by superoxide dismutases (SODs) into hydrogen
peroxide [2], or non-enzymatically converted into other ROS [3].
Hydrogen peroxide is relatively stable and can travel further distances
than superoxide and has the potential to generate reactive hydroxyl
radicals through interactions with iron or copper in cells by means of
the Fenton reaction. Superoxide can also react with nitric oxide (NO),
which is enzymatically produced by nitric oxide synthase (NOS), to
form peroxynitrite (ONOO−) [4] (Fig. 1). Peroxynitrite itself is
relatively stable and can travel several micrometers before decom-
posing into the highly reactive hydroxyl radical and nitrogen dioxide
[4].Physiological concentrations of ROS regulate various biological
processes, e.g. control of ventilation and erythropoietin production [5].
Furthermore, ROS are produced in vast quantities by immune cells in
order to kill pathogens and facilitate phagocytosis [6,7]. However, in
neuropathological disorders, including Alzheimer's disease, Parkinson's
disease, Huntington's disease and the neuroinﬂammatory disorder
multiple sclerosis (MS), ROS production overwhelms the antioxidant
capacity and contributes to cellular injury (for review see [8–11]).
2. Origin of free radical formation in MS pathology
2.1. Classiﬁcation of MS lesions
Multiple sclerosis (MS) is a chronic inﬂammatory disease of the
central nervous system (CNS) affecting both white and gray matter
[12,13]. The most predominant histopathological feature of MS is the
presence of focal demyelinated lesions scattered throughout the white
matter. The course of the disease is generally episodic, with frequent
intervals of exacerbations followed by periods of remission. The
relapsing-remitting phase is characterized by immune-mediated
responses, such aswidespreadmicroglial activation andmassive cellular
inﬁltrates in the CNS. In time, patients gradually develop secondary
progressive MS, which is mainly characterized by neuronal and axonal
degeneration and extensive cortical demyelination [12,14,15].
The initial phase of MS lesion formation is mainly characterized by
clusters of activatedmicroglia without evident signs of demyelination,
whereas in the active phase of MS lesion development monocyte-
Fig. 1. Schematic overview of ROS formation and detoxiﬁcation. Superoxide (O2. −) is
dismutated into hydrogen peroxide (H2O2) by superoxide dismutases, however in
combination with nitric oxide (NO) forms peroxynitrite (ONOO.). Subsequently,
hydrogen peroxide is either detoxiﬁed by endogenous antioxidant enzymes or in the
presence of transition metals converted into highly toxic hydroxyl radicals (OH·).
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demyelination process. Active lesions contain abundant activated
myelin-laden microglia and macrophages throughout the lesion area.
In time, active lesions gradually convert into chronic active lesions,
which are characterized by a hypocellular demyelinated gliotic center
with a hypercellular rim containing activated macrophages. In the
chronic lesion stage when inﬂammation has subsided hypertrophic
astrocytes form a dense network, the so-called astroglial scar [16].2.2. Activated microglia and macrophages are major cell source of ROS
The cellular source of free radical production largely depends on the
stage of the MS lesions. Both activated microglia and inﬁltrated
macrophages are able to generate vast amounts of proinﬂammatory
mediators and oxidizing radicals, such as superoxide, hydroxyl radicals,
hydrogen peroxide and nitric oxide [17]. Important sources of oxidizing
species in activated microglia and macrophages are the ROS-generating
enzymes myeloperoxidase, xanthine oxidase and NADPH oxidase.
Myeloperoxidase is a lysosomal enzyme which produces hypochlorous
acid (HOCl) from hydrogen peroxide and chloride anion. In homo-
genates ofMSwhite andgraymatter, demyelinationwas associatedwith
signiﬁcantly elevated myeloperoxidase activity [18,19]. In white matter
lesionsmyeloperoxidasewas predominantly expressed bymacrophages
and activated microglia within and in close vicinity of MS plaques,
emphasizing the key role of thesemyeloid cells in the generation of ROS.
Recent advances in the understanding of the pathology of MS
revealed that demyelinating lesions also exist within the graymatter. In
general, cortical MS lesions lack signiﬁcant macrophage inﬁltration,
however the gray matter part of leukocortical (type I) lesions contain a
rim of activated microglia [12,20]. Gray and colleagues demonstrated
that myeloperoxidase was expressed by a subset of activated microglia
in cortical lesions, suggesting that microglia-derived ROS might
contribute to gray matter demyelination [19].
Xanthine oxidase catalyzes the oxidation of hypoxanthine to
xanthine thereby generating large quantities of ROS, including
superoxide and its dismutation product hydrogen peroxide. In addition,
NADPH oxidase is a multi-subunit enzyme complex that is activated
under pathological conditions inmicroglia and catalyzes the production
of superoxide from oxygen. Evidence is accumulating that NADPH
oxidase represents a common pathway ofmicroglia-mediated neuronal
damage [21]. Remarkably, nothing is known about the expression
pattern of xanthine oxidase and NADPH oxidase in brain tissue derived
of MS patients although it is plausible that both enzymes contribute to
ROS production during the early phase of MS lesion formation. During
inﬂammatory conditions macrophages and microglia generate high
levels of nitric oxide by activation of inducible nitric oxide synthase.
Nitric oxide reacts with superoxide to form highly toxic peroxynitrite,
which in turn might attack tyrosine residues of proteins, thereby
affecting their function [22].2.3. Mitochondrial dysfunction contributes to ROS production
In later stages of MS pathogenesis when inﬂammation has abated,
other non-inﬂammatory pathogenic mechanisms, such as mitochondrial
dysfunction contribute to the formation of free radicals. Mitochondrial-
derived ROS are believed to play a major role in neurodegeneration, as
previously observed in Alzheimer's and Parkinson's disease [8–10].
Mitochondria are a constant source of ROS, due to electron leakage from
the electron transfer chain (ETC) [1,23]. Normally, the amount of ROS
produced by mitochondria is counteracted by local antioxidant enzymes.
However, mitochondrial ROS production can be markedly increased in
response to pathological events leading to cellular oxidative stress. In the
early 1990's, it was suggested that mitochondriamight be involved inMS
pathogenesis, as Leber's hereditary optic neuritis, which shares several
pathogeneticmechanismswithMS,was found to be caused bymutations
in mtDNA [24,25]. This led to a number of genetic studies in search of a
relationbetweenmitochondrial genotype andMS.Although some reports
described associations between mtDNA polymorphisms and MS [26,27],
up tonownopathogenicmtDNAmutationsassociatedwithMShavebeen
described [28].
More recently, mitochondrial alterations and mitochondria-derived
ROS have been implicated in axonal degeneration inMS [29,30]. Axonal
degeneration inMScanbedivided into two stages, theﬁrst representing
acute axonal injury in inﬂammatory MS lesion [31,32], and the second
being ‘slow burning’ axonal degeneration in non-inﬂammatory chronic
lesions [33]. Acute axonal injury is directly mediated by inﬂammation-
derived toxic molecules, including ROS and nitric oxide, whereas ‘slow
burning’ axonal degeneration is believed to be the consequence of intra-
axonal alterations caused by chronic demyelination. Upon demyelin-
ation, axonal conduction is blocked due to the absence of sodium
channels in acutely demyelinated segments. However, axonal conduc-
tion can be restored by redistribution of sodium channels along these
demyelinated segments [34]. This leads to an enormous inﬂux of
sodium, which can be counteracted by increasing Na+/K+ ATPase
activity. Na+/K+ATPase function depends on ATP, thusmitochondria in
demyelinated axons need to increase their ATP production to maintain
conduction. The increasedmitochondrial ATP production partially relies
on an increase inmitochondrial number, aswe and others have recently
shown, and is likely to lead to increased mitochondrial ROS production
[35,36].
Interestingly, increasedmitochondrial density inMS lesions coincided
with enhanced expression ofmitochondrial heat shock protein 70, awell-
deﬁnedmarker ofmitochondrial stress. Mitochondrial heat shock protein
70 was observed in axons and astrocytes in MS lesions, suggesting the
occurrence of ongoing mitochondrial oxidative stress [36]. Two, not
mutually exclusive, causes for increasedmitochondrial ROS production in
chronic demyelinated axons have been proposed. Firstly, increased
numbers of mitochondria may contribute to enhanced mitochondrial
ROS production, accumulating ROS damage tomitochondria and reduced
ATP production [37]. Alternatively, others suggested that mitochondria
have acquired oxidative damage during the inﬂammatory phase of MS,
leading to increasedmitochondrial ROS production and eventually axonal
energy deprivation in the later stages of the disease [38]. This might be
mediated by peroxynitrite, which is abundantly produced in the
inﬂammatory stage of MS lesions [39,40]. In experimental autoimmune
encephalomyelitis (EAE), a validated animalmodel forMS,mitochondrial
alterations and oxidative injury of mitochondrial proteins in axons even
precede inﬁltration of leukocytes [41,42]. This ﬁnding indicates that
mitochondrial changes initiate a cascade of molecular events leading to
axonal neurodegeneration in EAE that is not mediated by inﬂammatory
cells. Taken together, mitochondrial dysfunction and subsequent ROS
production are key players in degeneration of chronically demyelinated
axons inMS.Moreover, inﬂammation-derived ROS are a putative cause of
mitochondrial dysfunction in axons, although there is evidence support-
ing that mitochondrial dysfunction occurs before or in the absence of
inﬂammation.
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In the pathogenesis of MS, high amounts of ROS are produced which
overpower the antioxidant capacity resulting in oxidative stress. In turn,
oxidative stress will result in ROS-induced damage to biological
macromolecules suchaspolyunsaturated fatty acids (PUFA) inmembrane
lipids, essential proteins, and DNA/RNA. The CNS exhibits high oxygen
consumption and is enriched in PUFA,making it particularly vulnerable to
lipid peroxidation. Increased levels of indicators of oxidative stress and/or
decreased levels of antioxidant enzymes and antioxidants have been
detected in blood and cerebrospinal ﬂuid ofMS patients during the active
phases of disease, indicating that increased levels of ROS may have
resulted in the depletion of cellular antioxidants [43–49].
3.1. Oxidative damage in MS lesions
The occurrence of widespread oxidative damage in demyelinatingMS
plaques is supported by the expression ofmarkers of oxidative damage in
MS brain tissue. Oxidative damage to cellular membrane lipids generates
4-hydroxy-2-nonenal (4-HNE), a highly reactive aldehyde that is toxic to
CNS cells. In active demyelinating MS lesions 4-HNE accumulates in both
phagocytic macrophages and large hypertrophic astrocytes [50]. Nitric
oxide produced by inducible nitric oxide synthase can react with
superoxide to generate peroxynitrite, a diffusible free radical that can
react with tyrosine residues in proteins to form nitrotyrosine. Nitrotyr-
osine residues are present in high amounts in foamy macrophages and
largehypertrophic astrocytes throughout activedemyelinatingMS lesions
suggesting that both macrophages and astrocytes are a primary target of
oxidative damage [50–53]. Expression of 8-hydroxy-2’-deoxyguanosine
reﬂects the occurrence of oxidative damage to nucleotides and is
markedly increased in reactive astrocytes throughout inﬂammatory MS
lesions, whichmight reveal either oxidative damagedmitochondrial DNA
or increased RNA oxidation [50,54]. Interestingly, Bizzozero and cow-
orkers demonstrated increased protein carbonylation and nitrosative
stress in normal appearing white and gray matter in MS brain tissue
[55,56]. Taken together, there is ample evidence that extensive oxidative
injury occurs inMS plaques and that ROS-induced damage already occurs
in the earliest stages of neuroinﬂammation.
3.2. ROS induce pathological mechanisms of MS lesion formation
Alongside the damaging effect on essential biological molecules,
free radicals contribute to several key processes underlying MS
pathogenesis. In the initial phase of MS lesion formation, locally
produced ROS induce tight junction and cytoskeletal changes in brain
endothelial cells thereby facilitating transendothelial monocyte
migration [57,58]. ROS also play a crucial role in myelin phagocytosis
as blocking ROS productionwith NADPH oxidase inhibitors, lipoic acid
or catalase reduced the phagocytosis of myelin by macrophages [59].
Oligodendrocytes are highly susceptible to oxidative injury as they
contain high levels of PUFA that can react with ROS thereby triggering
lipid peroxidation. In addition, oligodendrocytes contain high intra-
cellular concentrations of iron [60] and reduced levels of antioxidant
enzymes and free radical scavengers [61–63].
Notably, immature oligodendrocyte progenitors (OPCs) are differen-
tially vulnerable to oxidative stress, due to lower levels of antioxidant
enzymes and anti-apoptotic proteins in combinationwith higher levels of
proapoptotic members [63,64]. Pro-oxidants like H2O2 strikingly inhibit
expression of myelin genes in human primary oligodendrocytes through
cellular redox alterations. Interestingly, French and colleagues recently
demonstrated that oxidative stress impairs OPC differentiation by
epigenetic mechanisms and decreased expression of genes that promote
maturation and enhanced expression of genes involved in oligodendro-
cyte dedifferentiation [65]. Together, these studies indicate that strategies
aimed at reinstating the redox balancemay offer protection against ROS-induced oligodendrocyte damage but also promote the differentiation of
OPCs into mature, myelin-producing cells and thus remyelination.
4. Antioxidant protection as a potential therapeutic target for MS
Since ROS play a pivotal role in the initial phase as well as the
chronic stage of MS, antioxidant therapy might be an attractive
approach to limit disease progression. Experimental animal studies
have demonstrated that dietary intake of exogenous antioxidants,
including ﬂavonoids and α-lipoic acid, reduce the progression and
clinical signs of EAE [58,66–74]. Despite promising results observed in
animal models for MS, data on successful antioxidant therapy in MS
patients is still limited emphasizing the need for epidemiological and
clinical studies on antioxidant strategies. Notably, there are a number
of disadvantages to the use of exogenous antioxidants for MS
treatment, as most antioxidant compounds do not efﬁciently cross
the blood–brain barrier and have a narrow therapeutic window.
Consequently, high quantities are generally required to achieve
protective effects in animal models for MS [44,75], illustrating the
need for other protective antioxidant mechanisms.
4.1. Regulation of endogenous antioxidant enzyme systems
To maintain a proper tissue redox balance and counteract oxidative
damage the central nervous system is equipped with an endogenous
antioxidant defense mechanism consisting of antioxidant enzymes.
Production of these cytoprotective enzymes is induced upon exposure
to ROS via a mechanism regulated at the transcriptional level (528).
Genes that code for proteins involved in ROS detoxiﬁcation share a
common promoter element, called the antioxidant response element
(ARE).ARE-mediated geneactivation is coordinatedbynuclear factor E2
related factor 2 (Nrf2), which upon exposure to electrophiles or ROS,
translocates to the nucleuswhere it binds ARE and activates antioxidant
enzyme gene transcription [76–78]. Under normal conditions Nrf2 is
linked to the repressor protein Kelch-like ECH associating protein 1
(Keap1) thereby promoting its degradation. Oxidative stress enables
Nrf2 to escape Keap1-mediated proteasomal degradation, leading to
Nrf2 stabilization, nuclear translocation and subsequent production of
an array of cytoprotective enzymes [79]. So far, over 200 Nrf2-driven
genes involved in detoxiﬁcation and antioxidant defense have been
identiﬁed, including superoxide dismutases (SODs) [80], glutathione
peroxidases [81], peroxiredoxins [82], catalase [83] and NAD(P)H:
quinone oxidoreductase 1 [84] (Fig. 2).
4.2. Regulation and potential protective roles of endogenous antioxidant
enzymes in MS pathogenesis
Endogenous antioxidant enzymes may reﬂect the occurrence of
oxidative stress. Preliminary data from our group revealed a signiﬁcant
upregulation of antioxidant genes (Fig. 3) and protein levels (Fig. 4) in
the course of EAE (unpublished data) and recently we demonstrated
that Nrf2-driven enzymes are highly expressed in activeMS lesions [50].
Endogenous antioxidant enzyme systems have distinct roles in
detoxiﬁcation of ROS and may be differentially regulated in MS.
Importantly, modulation of their expression of activity may exert
protective effects. For instance, superoxide dismutases (SODs) promote
dismutation of superoxide anion into molecular oxygen and hydrogen
peroxide. Increased gene and protein expression of SOD1 has been
detected in active demyelinating MS lesions [50,85]. In active
demyelinating MS lesions SOD1 staining was detected in foamy
macrophages and astrocytes [50]. Dismutation of superoxide by SODs
results in the formation of hydrogen peroxide, which is subsequently
converted by catalase, glutathione peroxidases, and peroxiredoxins.
Catalase itself is ubiquitously expressed in the CNS and is mainly
located in peroxisomes where it catalyzes the conversion of hydrogen
peroxide into water and molecular oxygen. Impaired peroxisomal
Fig. 2. The Nrf2 pathway. Under normal conditions Nrf2 associates with Keap1 and the actin cytoskeleton. Subsequently, Nrf2 is ubiquitinated and targeted for proteasomal
breakdown. Free radicals are able to oxidize cysteine residues of Keap1, which enables Nrf2 to escape Keap1-mediated proteasomal degradation. Next, Nrf2 translocates into the
nucleus where it binds to antioxidant response element (ARE) thereby inducing the production of antioxidant proteins.
144 J. van Horssen et al. / Biochimica et Biophysica Acta 1812 (2011) 141–150function has been demonstrated in CNS homogenates of rats suffering
fromEAE, whichwas accompanied by reduced catalase gene expression
and activity [86]. Catalase treatment of guinea pigs suffering from EAE
signiﬁcantly reduced demyelination of the optic nerves, increased BBB
integrity, and ameliorated neurological symptoms [86,87]. Administra-
tion of catalase reduced the severity of clinical signs in a rat model for
EAE [88]. Furthermore, upregulation of catalase expression via viral
vectors ameliorates EAE, implicating its positive effect in neuroinﬂam-
matory disorders [89,90]. InMS brain tissue catalase immunostaining is
observed inmyelin-ladenmacrophages and astrocytes [50]. Tajouri and
coworkers demonstrated that glutathione peroxidase gene expression
is signiﬁcantly increased in inﬂammatory MS lesions [85] and Guy and
colleagues showed that treatment with glutathione peroxidase reduces
loss of BBB integrity in chronic EAE [87], suggesting that glutathione
peroxidase plays a protective role in neuroinﬂammation.
Peroxiredoxins are a class of antioxidant enzymes which are
expressed in distinct CNS cell types, including neurons, astrocytes and
brain endothelial cells [91,92] and differentially regulated in neurode-
generative disorders [93]. Recently, we reported that peroxiredoxin-1
overexpression protected brain endothelial cells from ROS-induced cell
death, reduced adhesion and subsequent transendothelial migration of
monocytes and enhanced the integrity of the brain endothelial cell layer
[92]. Furthermore, we observed a striking increase of vascular peroxir-
edoxin-1 immunostaining in inﬂammatory lesions of experimental EAE
animals and inﬂammatory demyelinatingMS lesions. Enhanced vascular
peroxiredoxin-1 expression may reﬂect ongoing oxidative stress in EAE
and MS or it may function as a protective mechanism to limit ROS-
mediated damage and leukocyte inﬁltration into the CNS [92].
Heme oxygenase-2 is constitutively expressed in the CNS,while heme
oxygenase-1 is inducible by a variety of stimuli, including oxidative stress
[94]. Hemeoxygenases catalyze the rate-limiting step in the catabolismof
heme and break down the porphyrin ring into biliverdin, free iron and
carbon monoxide. Various research groups have demonstrated neuro-
protective effects of heme oxygenase-1 in vitro and in vivo [95,96].
Induction of EAE in heme oxygenase-1 knockout mice led to enhanced
CNS demyelination, paralysis, and mortality, as compared with wild type
mice [97]. Upregulation of heme oxygenase-1 [97,98] reduced the clinical
severity of EAE, whereas inhibition of heme oxygenase-1 markedly
exacerbated EAE. In contrast, treatment with the heme oxygenase-1
inhibitor tin-protoporphyrinattenuatedclinical scores inmurineEAE [99].
mRNA and protein levels of heme oxygenase-1 were strikingly upregu-
lated in brain tissue of EAE rats, (Fig. 2). In MS lesions, heme oxygenase
immunoreactivity was detected in activated microglia, inﬁltrated macro-
phages and hypertrophic astrocytes [50,100–102]. Heme oxygenase
degrades heme into biliverdin, which is subsequently converted by
biliverdin reductase into bilirubin, while the pro-oxidant iron issequestered and inactivated by co-induced ferritin. Bilirubin exerts potent
antioxidant activity, and both suppressed ongoing EAE and halted EAE
progressionwhenadministeredafter diseaseonset, likely by reducingBBB
permeability and oxidative damage [103]. Interestingly, bilirubin pro-
tected rat oligodendrocytes against hydrogen peroxide-mediated cell
death. Treatment with biliverdin reductase, like bilirubin, reduced
oxidative injury in EAE lesions and signiﬁcantly suppressed clinical
symptoms of EAE [104].
NQO1 is a cytosolic ﬂavoprotein that has broad-spectrum antioxi-
dant properties [105,106]. Besides their function as antioxidants, NQO1
and NQO2 function to maintain both α-tocopherol and coenzyme Q10
in their reduced antioxidant state. NQO1 is expressed in tissues that
require high levels of antioxidant protection, like lung respiratory
epithelium and the CNS [107,108]. NQO1 is predominantly found in
astrocytes and brain endothelial cells of healthy human brain tissue and
markedly upregulated in inﬂammatory MS lesions, particularly in
hypertrophic astrocytes and myelin-laden macrophages [109].
Although within MS lesions, the expression of antioxidant enzyme
systems is severely increased, there are still signs of ongoing oxidative
damage to brain tissue [50,51,53–56,110]. Future strategies to restore the
redox equilibrium may protect CNS cells form oxidative cell death and
limit pathological processes underlying MS lesion formation and disease
progression.
4.3. Mitochondrial antioxidant enzymes
Due to high levels of intracellular ROS and their susceptibility to
oxidative damage,mitochondria are equippedwith a robust antioxidant
defensemechanismconsistingof several antioxidant enzymes. SOD2, an
iron/manganese superoxide dismutase, resides in the mitochondrial
matrix where it catalyzes the reaction of superoxide into hydrogen
peroxide. Increased immunostaining of SOD2 in astroglia and microglia
has been observed in guinea pigs suffering from EAE [111] and SOD2
protein expression is upregulated in reactive astrocytes in active MS
lesions compared to surrounding normal appearing white matter [50].
Increased SOD2 levels by viral mediated transfer rescued ATP synthesis
and suppressed myelin degradation and neuronal injury in EAE [42].
In addition to SOD2, mitochondria contain speciﬁc enzyme systems
capable of detoxifying superoxide metabolites: the thioredoxin, gluta-
thione and glutaredoxin system [112]. These antioxidant systems are
widely expressed in various cellular compartments, with speciﬁc family
memberswithinmitochondria. Themitochondrial thioredoxin system is
composed of peroxiredoxin 3 (Prx3), peroxiredoxin (Prx5), thioredoxin
2 (Trx2) and thioredoxin reductase 2 (TrxR2) [113]. Prx3 and Prx5
convert hydrogen peroxide and peroxynitrite and are reduced by Trx2,
which is subsequently reducedbyTrxR2 [113]. Prx5hasbeen reported to
Fig. 3. Gene expression of Nrf2-driven antioxidant enzymes in the course of acute EAE. Gene expression of antioxidant enzymes HO-1 (A), SOD2 (B), and NQO1 (C) in the brainstem
of EAE animals at day 9 (n=2), 11 (n=7), 14 (n=7), and 17 (n=6) of EAE was analyzed using quantitative PCR as previously described [92]. mRNA expression is expressed as fold
change compared to control animals for each individual animal. Dotted line indicates fold change 1.0 and solid line indicates mean fold change per time point. (D) Summary of gene
expression of the antioxidant enzymes in A, B, and C. Data are expressed as fold change (mean ± SEM, compared to control). *, pb0.05, **, pb0.01, statistically different from 1.0, by
means of single-column t-test.
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chronicMS lesions [114]. In vitro and in vivo experiments have evidently
shown the protective properties of members of the thioredoxin-
peroxiredoxin system against neuronal damage [113,115,116], indicat-
ing a putative role in countering neuro-axonal damage in MS. The other
mitochondrial antioxidant systems, glutathione and glutaredoxin
systems work quite similar to the thioredoxin system (for review, see
[112]). Although there is ample evidence supporting theneuroprotective
effects of mitochondrial antioxidant systems in neuronal survival [117–
119], remarkably little is known about the expression and putative
protective role of mitochondrial antioxidant enzymes in MS pathology.4.4. Exogenous mitochondrial targeted antioxidants
Recently, antioxidant compounds have been developed which
selectively accumulate in themitochondrial matrix. Targeting of these
compounds to mitochondria is achieved by covalent attachment of
antioxidants like ubiquinol and vitamin E to a lipophilic cation.
Because of the large mitochondrial membrane potential, the anti-
oxidants accumulate within the mitochondria [120,121]. The mito-
chondrial targeted antioxidants MitoQ10 and MitoE2 have been
extensively tested in various models and have consistently proven
to protect cells from lipid peroxidation and ROS-mediated cell death
[120,122–125]. A promising feature of mitochondrial targeted anti-
oxidants is their widespread bioavailability. Upon intravenous and
oral administration, mitochondria-targeted antioxidants are rapidly
cleared from the bloodstream and accumulate in heart, brain, liver
and other tissues [126]. So far, only a few studies have tested efﬁcacy
of mitochondrial targeted antioxidants in vivo. MitoQ10 attenuated
hypertension and improved endothelial function in hypertensionprone rats [127] and limited tissue damage and mitochondrial
dysfunction in an ischemia-reperfusion model [128]. In contrast,
MitoE2 did not prevent loss of striatal neurons following perinatal
ischemia-reperfusion injury [129], suggesting that mitochondrial
oxidative damage is less important in this paradigm. Since mitochon-
drial ROS production contributes to MS pathogenesis mitochondria-
targeted antioxidant might be an attractive therapeutic strategy to
counteract axonal degeneration and neuronal injury. Therefore,
animal studies are needed to explore the putative beneﬁcial effects
of mitochondria-targeted antioxidants in animal models of neuroin-
ﬂammation and demyelination.5. Antioxidant therapy: Future perspectives
Taken together, there is growing evidence that ROS play a
pivotal role in several processes underlying the formation and
persistence of MS lesions (Fig. 5). We postulate that restoring the
redox balance in MS brain tissue might represent an attractive
therapeutic strategy to limit neuroinﬂammation and subsequent
oxidative tissue damage. Nrf2/ARE regulated antioxidant enzymes
are upregulated in CNS tissue of EAE animals and MS patients and
might act as an endogenous compensatory system to counteract
ROS-induced damage. Despite this cellular protective mechanism
oxidative damage to essential biological macromolecules is
abundant in inﬂammatory MS lesions, suggesting that although
Nrf2-mediated antioxidant enzymes are induced upon neuroin-
ﬂammation the response may be insufﬁcient to reduce ROS-
induced cellular damage. Hence, further activation of the Nrf2/ARE
system via monofunctional inducers might counteract oxidative
stress in neuroinﬂammatory diseases, such as MS. Monofunctional
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Fig. 5. ROS contribute to various processes underlying MS pathogenesis. 1) Upon adhesion to activated brain endothelial cells, monocytes produce ROS, which induce tight junction
gap formation and cytoskeleton changes thereby facilitating transendothelial monocyte migration. 2) Macrophages and activated microglia in MS brain tissue produce vast amounts
of ROS, which induce demyelination and oligodendrocyte cell death. In addition, ROS facilitate intracellular myelin degradation in macrophages. 3) In the inﬂammatory phase of the
disease macrophage- and microglia-derived ROS mediate axonal degeneration and 4) contribute to mitochondrial dysfunction in affected axons, which ultimately lead to increased
ROS production and decreased ATP production within demyelinated axons. 5) Dysfunctional mitochondria accumulate in chronically demyelinated axons, due to increased intra-
axonal energy demand. In these chronically demyelinated axons, mitochondrial ROS production further contributes to axonal injury.
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sulforaphane and 3-hydroxycoumarin, are well-tolerated, have the
ability to cross the BBB and promote transcription of endogenous
antioxidant enzymes [130,131].
Several reports have highlighted the protective effects of Nrf2
activation in reducing oxidative stress in both in vitro and in vivomodels
of neurodegenerative disorders. Induction of Nrf2-driven antioxidants
by dietary sulforaphane and tBHQ demonstrated beneﬁcial effects in
animal models for neurodegeneration, traumatic brain injury and
cerebral ischemia [132–136]. Importantly, postinjury administration
of sulforaphane, a naturally occurring compound present in cruciferous
vegetables, signiﬁcantly reduced loss of blood–brain barrier integrity
[135] and even improved cognitive function [137]. In an animal model
for neuroinﬂammation sulforaphane administration markedly reduced
microglial cell activation and concomitant production of inﬂammatory
mediators [138]. Chen and coworkers showed that sulforaphane
attenuated TNFα-induced monocyte chemoattractant protein-1
(MCP-1) and vascular cell adhesion molecule-1 (VCAM-1) expression
in endothelial cells [139,140]. Taken together, there is ample evidence
that activation of the Nrf2 pathway might play a protective role in the
pathogenesis of MS by operating on distinct levels. 1) Antioxidant
enzymes can directly scavenge ROS, thereby restoring BBB integrity. 2)
Nrf2 activation might reduce leukocyte adhesion and subsequent
transendothelial leukocyte migration. 3) Increased levels of antioxidant
enzymes might reduce microglial activation and limit myelin phagocy-
tosis and breakdown. 4) Upregulation of antioxidant enzymes might
prevent oxidative damage to neurons and oligodendrocytes. 5)
Restating the redox equilibrium by Nrf2 activation might promote
oligodendrocyte differentiation and thus limit demyelination and
subsequent axonal injury.Fig. 4. Nrf2-driven antioxidant enzyme expression in EAE brain tissue. In brain tissue o
immunostaining in close vicinity to perivascular macrophage inﬁltrates (B). HO-1 staining (
with an astrocyte-like morphology (E). Weak SOD2 immunostaining of blood vessels (F, arro
immunoreactivity is strikingly increased in areas with perivascular leukocyte inﬁltrates (G).
Immunohistochemistry was performed as previously described [92]. (A, F) original magniﬁNotably, clinical trials have demonstrated that oral administration of
BG00012, an oral formulation of dimethyl fumarate (DMF) has potent
anti-inﬂammatory and neuroprotective effects. Although the exact
molecularmechanismofDMFaction isnot fully understood,DMFand its
primarymetabolite monomethyl fumarate (MMF) are potent activators
of theNrf2-AREpathway. DMFamelioratedEAEdisease progression and
markedly inhibited cellular inﬁltration in the CNS. In the chronic phase
of EAE, both DMF andMMF reduced axonal injury and loss (Annemarie
van Dam, personal communication). Oral administration of BG00012
signiﬁcantly reduced the formation of both new gadolinium-enhancing
lesions as well as new T2-hyperintense lesions, indicating a decrease in
theoverall accumulation of new lesions. Interestingly, BG00012 reduced
T1-hypointense lesion development, indicating that activation of the
Nrf2 pathway might be neuroprotective and counteract tissue matrix
breakdown. Yet, future studies are warranted to gain more insight into
the molecular mechanisms by which Nrf2-driven antioxidant enzyme
production counteracts inﬂammatory and degenerative mechanisms
underlyingMSpathogenesis. Such studieswill signiﬁcantly increase our
understanding regarding the potential protective effects of Nrf2
activation and may lead to novel targets for future treatment strategies
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